Patient safety is at the heart of drug development and licensing processes. But the duty of care does not stop at launch. Manufacturers must satisfy strict regulatory demands throughout a product’s lifecycle, including re-labeling.
The revised FINMA circular 2018/3 “Outsourcing - Banks” has now been in effect for nearly a year. Experience has shown that institutions are having a hard time particularly with the risk-oriented monitoring of their outsourcing providers (including any sub-contractors these may have hired).
The latest issue of the European Family Business Barometer, a joint annual publication by European Family Businesses and KPMG, reveals a promising development for family businesses in Switzerland: Half of the survey’s respondents felt either positive or very positive about the next twelve months.